Huamin Zhai1, Duguang Li2, Qingbo Feng2, Xiaowei Qian1, Ling Li2, Jie Yao3. 1. Yangzhou University Medical College, Yangzhou, Jiangsu, 225001, China. 2. The Second Clinical College of Dalian Medical University, Dalian, Liaoning, 116044, China. 3. Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinic Medical College of Yangzhou University, Yangzhou, Jiangsu, 225001, China. Electronic address: docyao@hotmail.com.
Abstract
BACKGROUND: Pancreatic neuroendocrine tumours (pNETs) are a rare and heterogeneous group of tumours with an increasing incidence. Current staging criteria for pNETs remain limited and controversial. Meanwhile, the impact of chemotherapy on overall survival has not been fully defined. OBJECTIVES: The current study aimed to explore epidemiologic trends of pancreatic neuroendocrine tumours (pNETs). To determine feasible improvements to staging criteria and investigate the relationship between chemotherapy and survival. METHODS: A retrospective cohort study design was used to analyse annual cancer incidence rates, patient demographics, tumour site and stage, and treatment of pNETs. Data were obtained from the National Cancer Institute's SEER registry for all patients diagnosed with pNETs between January 1973 and December 2015. RESULTS: Patients diagnosed after 2010 were more likely to present with age greater than 45 years, T0, T1 status, N0 status, M0 status, and well differentiation. Current AJCC staging criteria was applicable to patients with well differentiation, but not other differentiation. The revised system, defined by Grade, T, N, and M status, could robustly discriminate between survival curves. Chemotherapy was associated with significantly improved survival for patients with poorly differentiated and undifferentiated tumour grading. CONCLUSIONS: Grade is superior to 'T', 'N', or 'M' status in predicting outcomes and selecting patients for chemotherapy. It is necessary and feasible to combine grade into current staging criteria.
BACKGROUND:Pancreatic neuroendocrine tumours (pNETs) are a rare and heterogeneous group of tumours with an increasing incidence. Current staging criteria for pNETs remain limited and controversial. Meanwhile, the impact of chemotherapy on overall survival has not been fully defined. OBJECTIVES: The current study aimed to explore epidemiologic trends of pancreatic neuroendocrine tumours (pNETs). To determine feasible improvements to staging criteria and investigate the relationship between chemotherapy and survival. METHODS: A retrospective cohort study design was used to analyse annual cancer incidence rates, patient demographics, tumour site and stage, and treatment of pNETs. Data were obtained from the National Cancer Institute's SEER registry for all patients diagnosed with pNETs between January 1973 and December 2015. RESULTS:Patients diagnosed after 2010 were more likely to present with age greater than 45 years, T0, T1 status, N0 status, M0 status, and well differentiation. Current AJCC staging criteria was applicable to patients with well differentiation, but not other differentiation. The revised system, defined by Grade, T, N, and M status, could robustly discriminate between survival curves. Chemotherapy was associated with significantly improved survival for patients with poorly differentiated and undifferentiated tumour grading. CONCLUSIONS: Grade is superior to 'T', 'N', or 'M' status in predicting outcomes and selecting patients for chemotherapy. It is necessary and feasible to combine grade into current staging criteria.
Authors: Courtney A Kaemmer; Shaikamjad Umesalma; Chandra K Maharjan; Devon L Moose; Goutham Narla; Sarah L Mott; Gideon K D Zamba; Patrick Breheny; Benjamin W Darbro; Andrew M Bellizzi; Michael D Henry; Dawn E Quelle Journal: Sci Rep Date: 2021-05-13 Impact factor: 4.379
Authors: Jon Arne Søreide; Jan Terje Kvaløy; Dordi Lea; Oddvar M Sandvik; Mohammed Al-Saiddi; Torjan M Haslerud; Herish Garresori; Lars N Karlsen; Einar Gudlaugsson; Kjetil Søreide Journal: Cancer Rep (Hoboken) Date: 2021-06-08